STARPHARMA HOLDINGS ORDINARY (SPL) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
Google NewsStarpharma Holdings (ASX:SPL) Unlocks New Milestone in Radiopharmaceutical Partnership - Kalkine
Starpharma Holdings (ASX:SPL) Unlocks New Milestone in Radiopharmaceutical Partnership Kalkine
Starpharma Holdings (ASX:SPL) Shares Climb as Radiopharmaceutical Program Gains Momentum - Kalkine
Starpharma Holdings (ASX:SPL) Shares Climb as Radiopharmaceutical Program Gains Momentum Kalkine
DEP radiopharmaceutical data supports patent application
other announcement
Positive DEP HER2-Lu preclinical data support Phase 1 entry
other announcement
Why Starpharma Holdings (ASX:SPL) Shares Decline 6% on Friday? - Kalkine
Why Starpharma Holdings (ASX:SPL) Shares Decline 6% on Friday? Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
FDA confirms path to DEP HER2 first-in-human study
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Change of Director's Interest Notice - C Maley
director_dealing announcement
Notification regarding unquoted securities - SPL
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Upfront payment of USD $5.5 million received from Genentech
other announcement
Australian Microcap Investment Conference presentation
other announcement
Change of Director's Interest Notice - R Thomas
director_dealing announcement
Notice of 2025 Annual General Meeting/Proxy Form
other announcement
Change of Director's Interest Notice - C Maley
director_dealing announcement
Presentation to Accompany License Agreement with Genentech
other announcement
Starpharma Announces License Agreement with Genentech
other announcement
2025 Appendix 4G and Corporate Governance Statement
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
DEP Presentation at Targeted Radio Therapies Conference
other announcement
SPL receives positive FDA feedback on DEP SN38 for PROC
other announcement
Change of Director's Interest Notice - Ms Cheryl Maley
director_dealing announcement
Notification regarding unquoted securities - SPL
other announcement
Results of 2024 Reconvened Annual General Meeting
other announcement